J
Jukka Mäenpää
Researcher at University of Oulu
Publications - 26
Citations - 1630
Jukka Mäenpää is an academic researcher from University of Oulu. The author has contributed to research in topics: Timolol & Microsome. The author has an hindex of 20, co-authored 25 publications receiving 1565 citations.
Papers
More filters
Journal ArticleDOI
Inhibition and induction of human cytochrome P450 (CYP) enzymes.
Journal ArticleDOI
Expression of xenobiotic-metabolizing cytochrome P450 Forms in human full-term placenta
Jukka Hakkola,Markku Pasanen,Janne Hukkanen,Olavi Pelkonen,Jukka Mäenpää,Robert J. Edwards,Alan R. Boobis,Hannu Raunio +7 more
TL;DR: Data show that several xenobiotic-metabolizing CYP genes are expressed in human placenta at a low level, and the significant of such low-level expression is unknown, but it may have local physiological or toxic consequences.
Journal ArticleDOI
Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver
Jukka Hakkola,Markku Pasanen,Raija Purkunen,Seppo Saarikoski,Olavi Pelkonen,Jukka Mäenpää,Anders Rane,Hannu Raunio +7 more
TL;DR: The results provide a comprehensive qualitative picture of the expression of CYP genes in families CYP1 through CYP4 in human adult and fetal liver.
Journal ArticleDOI
Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes
Jukka Mäenpää,Holger Sigusch,Hannu Raunio,Tuula Syngelmä,Pia Vuorela,Heikki Vuorela,Olavi Pelkonen +6 more
TL;DR: The results suggest that the coumarin-type compounds in particular interact with the active sites of Cyp2a-5 and CYP2A6, and the active Sites are structurally different, since a number of compounds inhibited mouse, but not human COH activity.
Journal ArticleDOI
Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects
TL;DR: Since there is a correlation between the plasma level of timolol and several haemodynamic effects – especially HR in the state of elevated β‐adrenergic tonus – the CYP2D6 poor metabolizers may be more prone to bradycardia during treatment with (aqueous) ophthalmic Timolol.